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The DNA of vertebrates contains tissue specific
patterns of methylated cytosine residues. These
methylation patterns are transmitted by clonal inheritance[1] through the strong preferance of mammalian DNA (cytosine-5) methyltransferase (DNAMTase) for hemimethylated DNA[2], and are established during early embryogenesis and
gametogenesis[3]. Newly replicated DNA lacks this
methylation in the nascent strand. Shortly after the
passage of the replication fork, a maintenance
DNA-MTase methylates CpG dinucleotides on the
newly synthesized strand, thereby recreating the
spectrum of methyl groups that existed prior to
replication. DNA methylation (5-methylcytosine[5-mCyt] content of DNA) plays a considerable role
in both normal development and carcinogenesis[4],
but there seems to be conflicting reports concerning
the role of DNA methylation in carcinogenesis. It
has been hypothesized that hypomethylation of
DNA facilitates aberrant gene expression in
tumorigenesis[5]. Some believe that hypermethylation of DNA leads to the causative alteration in tumorigenesis which involves inactivating tumor suppressor genes and marking chromosome regions for
deletion[6]. Some overlooked the importance of alterations in gene expression and thought that mutation played the key role[4]. All these help to achieve
a better understanding of the mechanisms underlying carcinogenesis. We believe that carcinogenesis is
a multistep/multistage process that occurs in animals[7] with more carcinogenesis than mutagenesis,
and that DNA methylation played multiple roles in
the transformation from a normal cell into a frank
malignancy.
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DNA METHYLATION AND CANCER

Mutations which occur at CpG dinucleotides in vertebrate DNA can be attributed to the hydrolytic
deamination of 5-mCyt and are easily recognized because of the nature of base substitution. Deamination of 5-mCyt dinucleotides results in the formation
of thyminephosphoguanosine (TpG). This still does
not account for the high frequency of mutagenesis
observed at CpG sites. Differences in the repairing
efficiencies of promutagenic lesions may be partly
responsible for this discrepancy. The guanosinethymine (G-T) misrepairs resulting from
deamination of 5-mCyt are believed to be more
difficult for the cell to repair, as thymine is a
normal component of DNA.
Mutations in the evolutionarily conserved
codons of the p53 tumor suppressor gene are common in diverse types of human cancer. The p53 mutational spectrum differs among cancers of the
colon, esophagus and liver. Transitions predominate in colon, whereas G:C to T:A transversions
are the most frequent substitutions observed in cancers of the liver. Mutations at adeninethymine (A:
T) base pairs are seen more frequently in esophageal
carcinomas than in other solid tumors. Most transitions in colorectal carcinomas are at CpG dinucleotide mutational hot spots. G-T transversions in
esophageal carcinomas are dispersed among numerous codons[8]. One copy of the short arm of chromosome 17, which harbors the p53 gene, is lost in
many human tumors including those of the colon
and rectum. In the colon carcinomas 75% - 80%
show a loss of both p53 alleles, one through
deletion, the other through a point mutation. The
point mutations are usually misense, giving rise to
an altered protein[9]. Cytosine-thymine (C-T) transitions at CpG sites are the most prevalent mutations
found in the p53 tumor suppressor gene in human
colon tumors and in the germline (Li-Fraumeni
syndrome). All of the mutational hot spots are
methylated to 5-mCyt, and it has been hypothesized
that the majority of these mutations are caused by
spontaneous hydrolytic deamination of this base to
thymine [10]. It is estimated that 75%-90% of hepatocellular carcinoma (HCC) cases are attributable to
hepatitis B virus. HBV DNA integrates into HCC
cells at random sites in the genome. It contains the
X gene, which codes for a protein HBX that modu-
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lates the transactivation of many cellular genes and
is a candidate viral oncoprotein. HBX protein binds
with p53 in vitro and in vivo[11], inhibits p53
sequence-specific DNA binding and transactivation
activities, partially disrupts p53 oligomerization and
prevents p53 binding to transcription-repair coupling factor ERCC3 [12]. HBV infection alone does
not influence the rate of p53 mutation, and aflatoxin B1 (AFB1) exposure is the most important factor
influencing mutation prevalence. AFB1 plays an etiological role in HCC carcinogenesis and indicates a
synergy between HBV and AFB1[13]. In patients
with liver tumors from geographical areas where
both AFB1 and HBV are cancer risk factors, most
mutations are at one nucleotide pair of codon 249[8].
Multiple gene-tic alterations occur in gastric
carcinomas, including point mutation of the ras
oncogene and the p53 tumor suppressor gene, amplification of the c-met, k-sam, and c-erbB-2/neu
genes, and loss of heterozygosity (LOH) of the bcl2, APC, and DCC genes. Genetic changes in the
transforming growth factor beta (TGF-β) type II
receptor gene or altered expression of its messenger
RNA[14] occur commonly in gastric cancer cells resistant to growth inhibitory action of TGF-β. Inactivation of the p53 gene through mutations and the allelic deletion may play an important role in gastric
tumorigenesis. These mutations may cause a conformational change in the p53 protein, resulting in the
loss of p53 suppression of the gastric cell growth
partly through disruption of the association of p53
protein with a cellular component[15]. Allelic loss
and mutation of the p53 gene are detected in over
60% of gastric cancers regardless of the histological
type. Several gastric cancer cell lines have shown
p53 gene abnormalities[16]. The c-met gene encoding
the receptor for hepatocyte growth factor (HGF) is
often amplified in advanced gastric cancer, particularly in 39% of scirrhous carcinomas, whereas c-met
amplification is extremely rare in esophageal and
colorectal cancers[17]. The interaction of c-met overexpressed tumor cells and HGF from activated stromal cells is involved in the morphogenesis and progression of gastric cancer. The K-sam gene encoding
receptor for keratinocyte growth factor is amplified
preferentially in the poorly differentiated scirrhous
cancer[18]. However, no K-sam amplification is seen
in esophageal and colorectal cancers. In general, Ksam amplification is independent of c-met amplification in scirrhous carcinoma, and c-erbB-2 gene
amplification is detected only in well differentiated
gastric cancer. Moreover, overexpression of c-erbB2 is closely correlated with livermetastases. c-Ki-ras
point mutation is observed in 9%-18% of well differentiated gastric cancers but not in poorly differentiated ones[19].
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M E C H A N I S M S O F D N A M E T H Y L AT I O N I N C A R CINOGENESIS

Both general hypomethylation and regional hypermethylation coexist in the genome of a wide variety
of human and animal cancers [5,6]. It has been suggested that changes in methylation may not play a
causal role in carcinogenesis and could be consequences of the transformed state of tumor cells and
that C-T transitions brought about by increased expression of the DNA methyltransferase play the key
role[4]. Beside DNA MTase induced mutations additional factors appear to be involved in the cancer
process. Cancers originate from a single cell that is
changed dramatically by a series of alterations to the
genome, e.g., mutation and changes in methylation
altered gene expression. Mutagenesis plays a role in
carcinogenesis. Mutated gene must be expressed to
exert an effect.
It has been suggested that reduction of DNA
MTase activity would lead to marked hypomethylation which can inhibit tumorigenesis [4,20]. Since
DNA methylation is critical in development and differentiation[21] of tumors, it is reasonable to propose
that hypomethylation at an intermediate level plays
a key role in carcinogenesis while excessive hypomethylation may not be compatible with the life
of the affected cells (e.g., owing to massive deregulation of gene expression). By this we mean that
initiated cells may die under the severe conditions of
hypomethylation and would not be available to form
tumors. Thus the fact that inhibition of methylation
may decrease tumor formation does not prove that
excessive DNA MTase activity is the sole mechanism
underlying carcinogenesis.
There are mechanistically and theoretically
plausible genotoxic mechanisms that support the
roles of both hypomethylation and hypermethylation of DNA (i.e. epigenetic changes) in
carcinogenesis. These involve mainly alterations in
normal gene expression (including tumor suppressor
genes). Altered DNA methylation not only affects
gene expression but also facilitates mutations, as 5mCyt can deaminate spontaneously to Thymine
(T). This indicates that elevated expression of the
DNA MTase may lead to increased 5-mCyt, and this
can increase the probability of C to T
transitions [4,22,23]. Moderate DNA-MTase increases
are not merely bystander effects, but could rather
constitute one of the earliest and fundamental
changes of neoplastic development[23]. Hypomethylation of DNA is associated with increased gene
expression[24]. Additionally, a decreased capacity or
fidelity of maintaining the normal methylation status of DNA may underlie the sensitivity of some
mouse strains to liver tumorigenesis, in which increased expression of oncogenes appears to be involved by facilitating tumor promotion[5,25,27]. The
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principal characteristic of the promotion stage of
the carcinogenesis that distinguishes it from the
stages of initiation and progression is its operational
reversibility, i.e., clones of initiated cells regress
when the promoting agent is withdrawn. The promotion stage ends when a lesion attains the capacity
for growth in the absence of a promotion stimulus,
i.e., when it is no longer reversible and can
progress to a frank malignancy[7]. Hypermethylation of specific regions of DNA has been identified
in cancer cells. For example, the Von Hippel Landau (VHL) tumor suppressor gene is hypermethylated and inactivated in a fraction of renal cell lines
and tumors that did not have mutations in the coding regions sequenced[6]. Regional chromosomal hypermethylation is related to areas believed to contain tumor suppressor genes at various target sites.
This regional hypermethylation in portions of the
genome normally unmethylated may inactivate tumor suppressor genes. The functional significance
would be the same as an inactivating mutation or as
the loss of an allele. Regional hypermethylation of
the retinoblastoma gene appears to inhibit transcription of this tumor suppressor genes[26]. Hypermethylation of the 5’CpG island of CDKN2/p16/MTS
(tumor suppressor gene located on chromosome
9p21) is frequent in cell lines and primary lung
tumors, gliomas and head and neck squamous cell
carcinomas. Furthermore, inactivation through
DNA methylation can occur not only in neoplasms
where deletion is frequent in cell lines (breast, renal
cells) but also in those which are not commonly associated with loss of p16 through homozygous deletion (colon and prostate). Hypermethylation of the
p16 gene promoter region is a common abnormality
of p16 gene in human cancer[27]. Nearly all acute
leukemias and 50% of chronic leukemias and lymphomas show extensive methylation of the estrogen
receptor (ER) gene CpG island[28]. Mutation in the
p53 tumor suppressor gene is believed to occur in
more than half of all solid tumors[29]. Approximately 24% of point mutations of p53 in human cancers
are C-T transitions at CpG dinucleotides[29]. All of
the mutational hot spots in the p53 gene occurring at
CpG are methylated [30-32], suggesting an involvement of 5-mCyt as an endogenous mutagen. It is important to not only determine which tumor suppressor genes lie in specific regions and their normal
functions but also demonstrate a causative role, perhaps by reversing their inactivation. Altered DNA
methylation leads to 5-mCyt which has intrinsic hypermutability as compared with C via deamination.
This causes C-T transitions[22]. In the presence of
low levels of S-adenosyl methionine, DNA-MTase
may be able to form uracil leading to C-T
transitions[22]. Therefore, the high rate of mutation
at CpG dinucleotides may be due, in part, to DNA-
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MTase mediated deamination[4,23], and inhibition of
DNA mismatch repair£Û23£Ý. Additionally, 5-mCyt
may influence carcinogenesis via inhibition of DNA
repair, leading to fixation of promutagenic
lesions[5,25]. However, the high percentage of mutations at CpG sites can not be explained solely by the
presence of 5-mCyt, as the methylation patterns of
the p53 gene are tissue independent, suggesting that
tissue specific methylation does not contribute to the
different mutation patterns at CpG sites seen in
tumors[32]. This supports the contention that the effect of DNA methylation alterations may vary in
different tissues and in the genesis of different tumor types.
The complex nature of the methylation role in
region of gene expression is illustrated by the insulin
growth factor type II receptor (Igf2r) gene. Both
hypomethylation of the 5’ flanking region and
methylation of a specific CpG site in an intron are
required for the occurrence of expression. The latter appears to be an imprinting signal, and hypomethylation at this site may silence the gene even
if the 5’flanking region remains hypomethylated[33].
The epigenetic properties of DNA methylation
are heritable and unlike the mutagenic effects of 5mCyt which do not involve alterations of the primary DNA sequence. Methylation of cytosine residues
contained in CpG islands of certain genes has been
inversely correlated with gene activity, but it is still
unclear whether this methylation is actually responsible for different activity states of a gene or is
merely the result of such changes. Methylation at a
CpG islands may lead to decreased gene expression
by a variety of mechanisms including disruption of
local chromatin structure, inhibition of transcription factor DNA, or by recruitment of proteins
which interact specifically with methylated sequences indirectly preventing transcription factor
binding [5,34] . Increased methylation and heterochromatization of CpG islands have been proposed as a mechanism for silencing the expression of
non-essential genes during the establishment of immortal cell lines.
CONCLUSION

The current literature provides a compelling basis
for suggesting that mutations arising secondarily to
deamination of 5-mCyt, C or both are an important
source of critical point mutations. Mutation, altered
gene expression, hypomethylation and hypermethylation may be all related to carcinogenesis which are
not mutually exclusive. Hypomethylation, hypermethylation and mutations may be important based
on different situations. The examination of DNA
methylation status provides the potential to discover
alterations in gene expression, cell proliferation,
mutation, chromatin aberrations and inactivation/

Javed Yakoob, et al. DNA methylation and digestive neoplasms

deletion of tumor suppressor genes in multifaceted
approach that fits the multistep process of
carcinogenesis. This notion can be supported by the
depiction of human colon carcinogenesis in which
roles for hypomethylation of DNA, mutation and
tumor suppressor gene inactivation are considered to
be relevant to the ultimate tumor formation [5,25] .
There is a need to address the functional significance of specific changes in methylation (e.g., how
the binding of transcating factors to specific genes is
affected by methylation), and changes in methylation that occur in target tissues prior to the appearance of frank malignancies. The overall goal should
be an understanding of changes in methylation and
how they facilitate movement of cells through the
different stages of carcinogenesis. This can be accomplished by keeping in perspective the fact that
cancer is a disease of the whole entity, and thus
there is a need to focus, though not exclusively, on
in vivo studies.

13
14

15

16
17
18
19
20
21
22
23

REFERENCES
1
2
3
4
5
6
7
8
9
10
11
12

Wigler M, Levy D, Perucho M. The somatic replication of DNA methylation.
Cell,1981;24(1):33-40
Graunbaum Y, Cedar H, Razin A. Substrate and sequence specificity of a eukaryotic DNA methylase.Nature,1982;295(5850):620-622
Chaillet JR, Vogt TF, Beier DR, Leder P. Parental specific methylation of an imprinted transgene is established during gametogenesis and progressive changes
during embryogenesis.Cell,1991;66(1):77-83
Laird PW, Grusby JL, Fazeli A, Dickson S, Edward JW, Li E et al.Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 1995;81(2):
197-205
Count JL, Goodman JI. Hypomethylation of DNA: an epigenetic mechanism
involved in tumor promotion.Mol Carcinogen,1994;11(1):185-188
Herman JG, Latif F, Weng YK, Lerman MI, Zbar B, Liu S et al. Silencing of the
VHL tumor suppressor gene by DNA methylation in renal carcinoma.Proc
Natl Acad Sci USA,1994;91(21):9700-9704
Pitot HC, Dragon YP. Facts and theories concerning the mechanisms of
carcinogenesis. FASEB J,1991;5(9):2280-2286
Hollestein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human
cancers.Science,1991;253(5015):49-53
Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature,
1991;351(6326):453-456
Schumutte C, Yang AS, Nguyen TDT, Beart RW, Jones PA. Mechanisms for
the involvement of DNA methylation in colon carcinogenesis. Cancer Res, 1996;
56(10):2375-2381
Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis BX antigen and p53 are
associated in vitro and in liver tissues from patients with primary hepatocellular
carcinoma.Oncogene,1993;8(5):1109-1117
Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B
virus X protein inhibits p53 sequence specific DNA binding transcriptional activity,

24
25
26
27
28
29
30
31
32
33
34

177
and association with transcription factor ERCC3. Proc Natl Acad Sci USA,
1994;91(6):2230-2234
Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT et al. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma.Lancet, 1992;339(8799):
943-946
Park K, Kim SJ, Bang YJ, Park JG, Kim NK, Robert AB et al. Genetic changes
in the transforming growth factor beta type II receptor (TGF-β) gene in human
gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β.
Proc Natl Acad Sci USA,1994;91(19):8772-8776
Matozoki T, Sakamoto C, Suzuki T, Matsuda K, Uchida T, Nakano O et al. p53
gene mutations in the human gastric cancer: wild type p53 but not mutant p53
suppresses growth of human gastric cancer cells.Cancer Res,1992;52(16):43354341
Tahara E, Sembo S, Tahara H. Molecular biological observations in gastric
cancer.Seminars in Oncology,1996;23(3):307-315
Kuniyasu H, Yasu W, Kitadai Y, Yokozaki H, Ito H, Tahare E. Frequent amplification of thec-met gene in scirrhous type stomach cancer. Biochem Biophys Res
Commun,1992;189(1):227-232
Katoh M,Terada M.Oncogenes and tumor suppressor genes. In: Nishi M,
Ichikawa H,Nakajima T et al,eds. Gastric cancer. Tokyo: Springer-Verlag,
1993:196-208
Tahara E. Molecular mechanisms of stomach carcinogenesis. J Cancer Res Clin
Oncol,1993;119(5):265-272
Macleod AR, Szyf M. Expression of antisense to DNA methyltransferase mRNA
induces DNA demethylation and inhibits tumorigenesis.J Biol Chem, 1995;
270(14):8037-8043
Li E, Beard C, Jaenisch R. Role for demethylation in genomic imprinting.
Nature,1993;366(6453):362-365
Yang AS, Shen JC, Zingg JM, Mi S, Jones PS. Hha I and Hha II DNA methyltransferases bind DNA mismatches methylate uracil and block DNA repair. Nucleic Acids Res,1995;23(8):1380-1387
Wu J, Herman JG, Wilson G, Lee YR, ChiuYen RW, Mabry M et al. Expression of prokaryotic Hha I DNA methyltransferase is transforming and lethal to
NIH 3T3 cells.Cancer Res,1996;56(3):616-622
Ferguson AT, Lapidus RG, Baylin SB, Davidson NE. Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer can reactivate estrogen receptor gene expression.Cancer Res,1995;55(11):2279-2283
Counts JL, Goodman JI. Molecular and cellular mechanisms. In: Liver regeneration and carcinogen.New York: Academic Press,1995:227-255
Greger V, Debus N, Lohmann D, Hopping W, Passage E, Horsthemke B. Frequency and parental origin of hypermethylated RBI alleles in retinoblastoma. Hum
Genet,1994;94(5):491-496
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JPJ, Davidson NE. Inactivation of
the CDKN2/16/MTS gene is frequently associated with aberrant DNA methylation in all common human cancers.Cancer Res,1995;55(20):4525-4530
Issa JPJ, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE et al. The
estrogen receptor CpG island is methylated in most haemopoetic neoplasms.
Cancer Res,1996;56(5):973-977
Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer aetiology and molecular pathogenesis.Cancer
Res,1994;54(18):4855-4878
Rideout WM, Coetzee GA, Olumi AF, Jones PA. 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science, 1990;249
(4974):1288-1290
Mague AN, Jones PA. Ubiquitous and tenacious methylation of the CpG site in
codon 248 of the p53 gene may explain its frequent appearance as a mutation hot
spot in human cancer.Mol Cell Biol,1994;14(6):4225-4232
Tornaletti S, Pfeifer GP. Complete and tissue independent methylation of CpG
sites in the p53 gene: implications for mutations in human cancers. Oncogene,
1995;10(8):1493-1499
Stoger R, Kubicka P, Liu CG, Kafri T, Razin A, Cedar H et al. Maternal specific methylation of the imprinted mouse Igf 2r locus identifies the expressed locus
as carrying the imprinting signal.Cell, 1993;73(1):61-71
Bird AP. The essentials of DNA methylation. Cell, 1992;70(1):5-8

